INTRODUCTION
Fatigue is a common complaint in general practice, affecting up to one third of the population. [1] [2] [3] [4] [5] Similarly, iron deficiency is a frequent disorder affecting about one fourth of menstruating women, as indicated in a French survey which defined iron deficiency by serum ferritin concentrations below 15 ng/mL. [6] [7] [8] Women are particularly at risk to develop either or both of these conditions. 9, 10 Different studies have suggested that iron deficiency can cause fatigue symptoms. [11] [12] [13] Clinical studies indicate an association between the status of body iron stores and aerobic adaptation during exercise [14] [15] [16] as well as cognitive function. 17, 18 Recently, Anker et al. showed intravenous iron to improve clinical disease, functional capacity, and quality of life in iron-deficient, non-anaemic patients with chronic heart failure. 14 Verdon et al. demonstrated that oral iron supplementation improved fatigue in a subgroup of premenopausal non-anaemic women with iron deficiency. 13 Similarly, Beutler et al. showed that women with normal haemoglobin concentration but depleted or reduced bone marrow iron stores experienced improvements in fatigue following oral iron therapy. 11 However, oral iron administration has limitations. It is often accompanied by gastrointestinal side effects and only about 10% of orally administered iron is absorbed by the body. 6 Investigation of any therapeutic approach to reduce fatigue can be influenced by a strong placebo effect, 19 making a placebo-controlled and blinded study design essential to draw conclusions for medical practice. Prior studies analysing the effect of iron supplementation on fatigue improvement were performed with oral iron, which use only.
For personal at KANTONSSPITAL ST GALLEN on September 14, 2011. bloodjournal.hematologylibrary.org From 5 can result in an unintended unblinding of patients due to intestinal side effects and stool colouring and thus influence study results. This is the first study to investigate the efficacy of intravenous iron in the treatment of fatigue in non-anaemic patients (women) with low serum ferritin concentration.
use only. 
Inclusion and exclusion criteria
Premenopausal, menstruating women ≥ 18 years of age who presented with fatigue were evaluated for inclusion in the study. Inclusion criteria were serum ferritin concentration ≤ 50 ng/mL, haemoglobin concentration ≥ 120 g/L, and adequate contraception for the study period. Exclusion criteria were pregnancy, intake of gestagens repressing menstruation, physical or mental disorders, medication affecting physical or mental performance, iron treatment in the 4 weeks prior to enrolment, and history of hypersensitivity to any iron medication. Patients were withdrawn from the study if serum ferritin concentration exceeded 800 ng/mL or if transferrin saturation exceeded 50% during the study period.
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Study design
The FERRIM trial was a randomised, double-blinded, placebo-controlled study.
Patients were randomised to receive either a cumulative intravenous dose of 800 mg iron as iron(III)-hydroxide sucrose or intravenous placebo during 2 weeks. The use only.
For personal at KANTONSSPITAL ST GALLEN on September 14, 2011. bloodjournal.hematologylibrary.org From primary study objective was to determine the efficacy of iron compared to placebo in decreasing fatigue 6 weeks after treatment initiation. Secondary objectives were to determine the impact of iron supplementation on serum ferritin and haemoglobin concentration and to confirm the safety of intravenous iron sucrose. Patients were followed-up for 12 weeks. Subgroups of the study population were analysed to investigate the influence of the serum iron status at baseline on the efficacy of iron treatment.
Randomisation and blinding
The randomisation schedule was generated by Cardinal Health Germany GmbH (Schorndorf, Germany). In total, 172 randomisation numbers were generated.
The control group received placebo (0.9% saline). It was made sure through organisational measures that neither the patient nor the investigator could become aware of whether the active group (dark brown solution) or placebo (colourless solution) was administered. The study medication was prepared and administered by a staff member other than the investigator. Both the infusion bag and the injection site were covered, and non-transparent tubing was used, ensuring that the patient could not see the infusion solution at any time. The investigator was not present during the infusion.
Study medication
Treatment was delivered on 4 days during the first two weeks of the study by a 
Fatigue scores
Fatigue was assessed at baseline, and after 6 and 12 weeks using the Brief Fatigue Inventory questionnaire (BFI). 21, 22 Patients were asked to rate the severity of fatigue on a scale from 0 (no fatigue) to 10 (maximum imaginable fatigue) answering standardised questions. Three questions addressed the level of fatigue at its worst, its usual, and current level during the last 24 hours; six questions were aimed at gauging the interference of fatigue with aspects of daily life, including general activity, mood, walking ability, work/housework, relations with other people, and enjoyment of life. According to the original publication validating the BFI, total fatigue score was obtained by calculating the mean of the resulting scores for these questions. 21, 22 Additionally, change in fatigue was assessed 6 and 12 weeks after treatment initiation by the Short Performance Inventory questionnaire (SPI). Patients were asked to categorise their current level of fatigue compared with the situation at baseline as improved (slightly better, much better, or completely resolved) or not improved.
Laboratory parameters
The concentrations of haemoglobin, iron, serum ferritin, transferrin, and C-reactive protein were measured at baseline and after 6 and 12 weeks. Patients' levels of use only.
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Adverse events
Adverse events were reported by the patients or assessed by the study physicians at each visit. Adverse events were classified as "serious" or "not serious" and as "drug-associated" or "not drug-associated". All patients who received at least one dose of study medication were included in the analysis.
Statistical analysis
Results with parametric distribution are presented as mean values (± 1 standard use only.
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RESULTS
Study population and baseline characteristics
Of 116 premenopausal women presenting with fatigue, 90 were included in the study. Median fatigue score of the study population was 4.5 at baseline as assessed on a scale from 0 to 10 using the BFI questionnaire. Thus, the majority of study patients presented with fatigue levels previously defined as "low" or "moderate". 21, 22 Of the 90 patients, 43 (48%) were randomised to receive intravenous iron (4x200 mg iron as iron(III)-hydroxide sucrose) and 47 (52%) to receive intravenous placebo (4x200 mL 0.9% saline). Forty-two iron treated patients and 44 placebo treated patients underwent post-baseline evaluation (Figure 1 ).
At baseline, there was no significant difference between the iron and the placebo group with regard to fatigue (4.0 vs. 4.7, p>0.10), serum ferritin concentration (24 vs. 20 ng/mL, p>0.10), or transferrin saturation (20 vs. 25%, p>0.10). The study groups were also well randomised in age, height, body weight, blood pressure, heart rate, and laboratory parameters ( Figure 2 , Table 1 ).
Change in fatigue after 6 weeks
Fatigue decreased in both study groups during the first 6 weeks after treatment initiation as assessed by the BFI score ( Figure 2 ). After 6 weeks, median fatigue decreased by 1.1 in the iron group and by 0.7 in the placebo group (p=0.07; Table 2 ). Improvement in fatigue 6 weeks after treatment start, as evaluated by the SPI, was reported by 65% of iron-treated and 40% of placebo-treated patients (p=0.02, Table   2 ). The most prominent difference between the two study groups was observed in those patients who judged their fatigue to be "much better" after 6 weeks of use only.
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Change in iron status after 6 weeks
In iron-treated compared to placebo-treated patients, a significant increase in serum ferritin concentration (98 ng/mL vs. 1 ng/mL; p<0.001) and transferrin saturation (9% vs. 2%; p=0.006) was observed during the 6 weeks following treatment initiation (Table 2 ). In contrast, haemoglobin levels remained normal and constant in both study groups during this period. As inflammation marker, C-reactive protein remained stable in both groups throughout the study period.
Subgroup analyses
The World Health Organisation (WHO) has defined a cut-off serum ferritin concentration of 15 ng/mL to identify iron deficiency. 24 Therefore, in an additional analysis, the WHO criterion was applied to the present study: efficacy of iron was evaluated in the subgroups of patients with serum ferritin concentration Table 3 and Figure 3 ). And improvement in fatigue, as assessed by the SPI, was reported by 82% of irontreated patients compared with 47% of placebo-treated patients (p=0.03; Table 3 ).
No significant differences between the study groups in BFI or SPI score at 6 weeks were observed in patients with baseline serum ferritin >15 ng/mL (Table 3) .
Similarly, in patients with transferrin saturation ≤ 20% at baseline, administration of iron resulted in a significantly greater reduction in fatigue than administration of placebo (BFI, p=0.01; SPI, p=0.002). However, patients with transferrin saturation >20% experienced no significant reduction in fatigue (both questionnaires p>0.10).
Follow-up after 12 weeks
The decrease in fatigue (BFI) between baseline and 12 weeks was 1.3 in the iron group and 0.9 in the placebo group (p>0.1), and improvement in fatigue (SPI) was reported by 63% of iron-treated patients and by 34% of placebo-treated patients (p=0.006). Improvements in serum ferritin concentration and transferrin saturation in iron treated compared to placebo treated patients remained significant after 12 weeks (p<0.001 and p=0.006, respectively; Table 4 ).
Among patients with a baseline serum ferritin concentration ≤ 15 ng/mL, the median decrease in fatigue score between baseline and 12 weeks was 2.3 and 0.7 in the iron and the placebo groups, respectively (p=0.03). Improvement in fatigue was reported by 82% of iron-treated patients and by 35% of placebo-treated patients (p=0.005; Table 4 ).
Adverse events
Evaluation of adverse events was performed throughout the study period and included 89 patients who each received at least one dose of study medication. The study groups did not differ significantly in the number of patients reporting adverse events or in the number of adverse events per patient (Table 5) . One serious adverse event was observed in the iron group (appendicitis) and one in the placebo group (traffic accident). Neither was classified as drug-associated.
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Seventeen drug-associated adverse events were reported among 9 patients treated with intravenous iron while 4 drug-associated adverse events were reported among 3 placebo-treated patients ( Table 5) . The difference between the study groups was significant regarding the number of patients reporting drug-associated adverse events (p=0.05). However, none of these drug-associated events were considered serious -the most frequently observed were nausea, chills, and headache ( Table 5 ).
The occurrence of these drug-associated adverse events was limited to the period of drug administration. A total dose of 800 mg intravenous iron administered over two weeks resulted in a marked increase in serum ferritin concentration (98 ng/mL), which indicated sufficient replenishment of body iron stores. Iron administration, however, did not influence haemoglobin concentration, which was in the normal range at baseline and remained constant during the observation period in both iron-treated and placebotreated patients. Thus, the fatigue-reducing effects of iron therapy reflect the nonuse only. These enzymes catalyse essential biochemical reactions, e.g., the formation of deoxyribonucleotides and aerobic oxidation of carbohydrates and fatty acids in the mitochondrial citric acid cycle of the respiratory chain.
25-27
The results of this study are in line with previous studies indicating a beneficial effect of oral iron therapy in comparable patient groups. [11] [12] [13] 18 Oral iron treatment, however, can be accompanied by gastrointestinal side effects and usually requires administration over several months since intestinal iron absorption is low; 6 both of these factors affect patients' adherence to therapy. In contrast, intravenous iron can efficaciously replenish iron stores with a good safety and tolerability profile. 14 In this study, drug-associated adverse events were observed more frequently in irontreated (21%) than placebo-treated (7%) patients. However, these events (mainly nausea, chills, and headache) were not serious and occurrence was limited to the period of administration.
Improvement in fatigue after 6 weeks was reported by 40% of placebo-treated patients. Further evaluation of this strong placebo effect showed a significant correlation between baseline fatigue and decrease in fatigue (r=0.38, p=0.009):
patients with high initial fatigue showed a strong response to placebo. This highlights the importance of the emotional component of fatigue in patients who considered themselves to be severely fatigued. 21, 22 This observation may be accurate for the present, besides iron-deficient otherwise healthy study population use only. Of note, it is always recommended to carefully search for somatic, psychological and/or social causes of fatigue. Even if a low serum ferritin value is found, a serious cause of iron deficiency, such as gastrointestinal bleeding, malabsorption syndrome, or gynecological diseases must be considered even in premenopausal women.
Conclusion
Intravenous administration of 800 mg iron improved fatigue in iron deficient, nonanaemic women with a good safety and tolerability profile. For personal at KANTONSSPITAL ST GALLEN on September 14, 2011. bloodjournal.hematologylibrary.org From
